IMMX

Immix Biopharma, Inc.

Healthcare
Biotechnology
$676M market cap

Forecast run · Oct 29, 2026Upside rank 169 of 3,186

Model Signal

ForecastQ Daily Probabilities

58.1%

34.9%

45.2%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$8.15

Price target$23.67

Implied move+190.4%

Analysts6

ForecastQ Portfolios

Healthcare Healthcare signal →

Company Profile

Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.